CHANGE IN NUMBER OF SHARES AND VOTES IN EPISURF MEDICAL AB

Episurf Medical AB has, in accordance with information previously announced, conducted a new issue of shares with preferential rights for the company’s shareholders. This has resulted in changes in the number of shares and votes in the company.

Through the new issue and the private placement, the number of A-shares has increased by 2,985,597 to 6,386,468 and the number of B-shares by 11,614,094 to 24,163,027. Consequently, the total number of shares has increased by 14,599,691 to 30,549,495 and the total number of votes by 20,570,885 to 43,322,431

For more information, please contact:

Pål Ryfors, acting CEO, Episurf Medical
 

Tel: +46 (0) 709 62 36 69

Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.

This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 11.00 CET on 31 March 2017.

Tags:

About Us

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.

Subscribe

Documents & Links